Modality
Multispecific
MOA
IL-23i
Target
LAG-3
Pathway
RAS/MAPK
CholangiocarcinomaPTSDT2D
Development Pipeline
Preclinical
~Apr 2010
→ ~Jul 2011
Phase 1
~Oct 2011
→ ~Jan 2013
Phase 2
~Apr 2013
→ ~Jul 2014
Phase 3
~Oct 2014
→ ~Jan 2016
NDA/BLA
~Apr 2016
→ ~Jul 2017
Approved
Oct 2017
→ Jul 2031
ApprovedCurrent
NCT07133096
2,738 pts·PTSD
2017-10→2031-07·Completed
NCT05272340
403 pts·Cholangiocarcinoma
2021-04→2030-01·Active
NCT07744717
2,908 pts·T2D
2025-06→2028-09·Active
6,049 total pts3 indications
CompletedCurrentUpcoming
Catalysts (3)
2028-09-282.5y awayPh3 Readout· T2D
2030-01-153.8y awayPh3 Readout· Cholangiocarcinoma
2031-07-025.3y awayPh3 Readout· PTSD
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
Approved
Complet…
Approved
Active
Approved
Active
Catalysts
Ph3 Readout
2028-09-28 · 2.5y away
T2D
Ph3 Readout
2030-01-15 · 3.8y away
Cholangiocarcinoma
Ph3 Readout
2031-07-02 · 5.3y away
PTSD
ActiveCompleted|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07133096 | Approved | PTSD | Completed | 2738 | UPCR |
| NCT05272340 | Approved | Cholangiocarcinoma | Active | 403 | EASI-75 |
| NCT07744717 | Approved | T2D | Active | 2908 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| GSK-6983 | GSK | Phase 2 | ALK | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| Polazasiran | Amgen | Phase 2 | LAG-3 | |
| Zenotapinarof | Vertex Pharma | Preclinical | CD38 | |
| ALN-6288 | Alnylam | Approved | LAG-3 | |
| Sovarelsin | Alnylam | Phase 2/3 | LAG-3 | |
| Bemasotorasib | Exelixis | Phase 2 | CD38 | |
| Tirasotorasib | Viking Therapeutics | Phase 1 | CFTR | |
| Motasacituzumab | Olema | NDA/BLA | FLT3 |